14.10.2021 18:10

Will Gilead (GILD) Beat Estimates Again in Its Next Earnings Report?

Folgen
Werbung
If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Gilead Sciences (GILD). This company, which is in the Zacks Medical - Biomedical and Genetics industry, shows potential for another earnings beat.When looking at the last two reports, this HIV and hepatitis C drugmaker has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 3.61%, on average, in the last two quarters.For the most recent quarter, Gilead was expected to post earnings of $1.76 per share, but it reported $1.87 per share instead, representing a surprise of 6.25%. For the previous quarter, the consensus estimate was $2.06 per share, while it actually produced $2.08 per share, a surprise of 0.97%.Price and EPS SurpriseWith this earnings history in mind, recent estimates have been moving higher for Gilead. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the company is positive, which is a great sign of an earnings beat, especially when you combine this metric with its nice Zacks Rank.Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven.The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.Gilead has an Earnings ESP of +5.23% at the moment, suggesting that analysts have grown bullish on its near-term earnings potential. When you combine this positive Earnings ESP with the stock's Zacks Rank #3 (Hold), it shows that another beat is possibly around the corner.When the Earnings ESP comes up negative, investors should note that this will reduce the predictive power of the metric. But, a negative value is not indicative of a stock's earnings miss.Many companies end up beating the consensus EPS estimate, but that may not be the sole basis for their stocks moving higher. On the other hand, some stocks may hold their ground even if they end up missing the consensus estimate.Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here.
Weiter zum vollständigen Artikel bei "Zacks"
Quelle: Zacks

Nachrichten zu Gilead Sciences Inc.

  • Relevant
  • Alle
  • vom Unternehmen
  • Peer Group
  • ?

Um Ihnen die Übersicht über die große Anzahl an Nachrichten, die jeden Tag für ein Unternehmen erscheinen, etwas zu erleichtern, haben wir den Nachrichtenfeed in folgende Kategorien aufgeteilt:

Relevant: Nachrichten von ausgesuchten Quellen, die sich im Speziellen mit diesem Unternehmen befassen

Alle: Alle Nachrichten, die dieses Unternehmen betreffen. Z.B. auch Marktberichte die außerdem auch andere Unternehmen betreffen

vom Unternehmen: Nachrichten und Adhoc-Meldungen, die vom Unternehmen selbst veröffentlicht werden

Peer Group: Nachrichten von Unternehmen, die zur Peer Group gehören

Analysen zu Gilead Sciences Inc.

  • Alle
  • Buy
  • Hold
  • Sell
  • ?
15.06.2020Gilead Sciences kaufenDZ BANK
15.03.2019Gilead Sciences OutperformBMO Capital Markets
03.01.2019Gilead Sciences OutperformOppenheimer & Co. Inc.
26.10.2018Gilead Sciences OverweightBarclays Capital
01.10.2018Gilead Sciences OverweightCantor Fitzgerald
15.06.2020Gilead Sciences kaufenDZ BANK
15.03.2019Gilead Sciences OutperformBMO Capital Markets
03.01.2019Gilead Sciences OutperformOppenheimer & Co. Inc.
26.10.2018Gilead Sciences OverweightBarclays Capital
01.10.2018Gilead Sciences OverweightCantor Fitzgerald
26.07.2018Gilead Sciences NeutralRobert W. Baird & Co. Incorporated
05.10.2017Gilead Sciences PerformOppenheimer & Co. Inc.
09.03.2017Gilead Sciences NeutralUBS AG
29.04.2016Gilead Sciences HoldMaxim Group
14.12.2012Gilead Sciences neutralGoldman Sachs Group Inc.
25.06.2010Gilead Sciences ausgestopptDer Aktionär
22.10.2009Gilead Sciences underperformWedbush Morgan Securities Inc.
10.02.2006Gilead Sciences underweightPrudential Financial
06.12.2005Gilead Sciences underweightPrudential Financial

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Gilead Sciences Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"

Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"

Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen
Werbung
Werbung
Werbung
Werbung
Börse Stuttgart Anlegerclub
Werbung

Heute im Fokus

US-Börsen schließen im Minus -- DAX geht tiefer ins Wochenende -- AstraZeneca erwägt wohl IPO der Impfstoffsparte -- Allianz verspricht Dividendenwachstum -- Tesla, DiDi, Aurubis, Daimler im Fokus

Porsche SE verlängert Pötsch-Vorstandsmandat. Walgreens Boots Alliance prüft wohl Verkauf von britischer Tochter Boots. BioNTech-Chef erwartet Notwendigkeit von neuem Impfstoff. Nordex sichert sich Großauftrag. US-Jobwachstum gerät im November überraschend ins Stocken. VW senkt Absatzziel für ID-Elektromodelle in China.

Umfrage

Wie bewerten Sie die Verhandlungsergebnisse und künftigen Pläne der Ampelkoalition?

finanzen.net zero
finanzen.net zero

Oskar

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln